questionsmedicales.fr
Maladies du système nerveux
Maladies du système nerveux central
Encéphalopathies
Épilepsie
Syndromes épileptiques
Épilepsies myocloniques
Épilepsies myocloniques : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Épilepsies myocloniques : Questions médicales les plus fréquentes",
"headline": "Épilepsies myocloniques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Épilepsies myocloniques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-27",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Syndromes épileptiques",
"url": "https://questionsmedicales.fr/mesh/D000073376",
"about": {
"@type": "MedicalCondition",
"name": "Syndromes épileptiques",
"code": {
"@type": "MedicalCode",
"code": "D000073376",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Épilepsies myocloniques progressives",
"alternateName": "Myoclonic Epilepsies, Progressive",
"url": "https://questionsmedicales.fr/mesh/D020191",
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques progressives",
"code": {
"@type": "MedicalCode",
"code": "D020191",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493.063.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Épilepsie myoclonique juvénile",
"alternateName": "Myoclonic Epilepsy, Juvenile",
"url": "https://questionsmedicales.fr/mesh/D020190",
"about": {
"@type": "MedicalCondition",
"name": "Épilepsie myoclonique juvénile",
"code": {
"@type": "MedicalCode",
"code": "D020190",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493.063.670"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques",
"alternateName": "Epilepsies, Myoclonic",
"code": {
"@type": "MedicalCode",
"code": "D004831",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Pasquale Striano",
"url": "https://questionsmedicales.fr/author/Pasquale%20Striano",
"affiliation": {
"@type": "Organization",
"name": "IRCCS Istituto \"Giannina Gaslini\", Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Marte Syvertsen",
"url": "https://questionsmedicales.fr/author/Marte%20Syvertsen",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway."
}
},
{
"@type": "Person",
"name": "Deb K Pal",
"url": "https://questionsmedicales.fr/author/Deb%20K%20Pal",
"affiliation": {
"@type": "Organization",
"name": "Department of Basic & Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Jeanette Koht",
"url": "https://questionsmedicales.fr/author/Jeanette%20Koht",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Circulating Immune Complexes and Complement Activation in Sensitized Kidney Transplant Recipients.",
"datePublished": "2024-10-10",
"url": "https://questionsmedicales.fr/article/39456685",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms252010904"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tear fluid and complement activation products in tears after ocular surgery.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37464366",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-03037-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36752022",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15730"
}
},
{
"@type": "ScholarlyArticle",
"name": "Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.",
"datePublished": "2023-08-09",
"url": "https://questionsmedicales.fr/article/37622108",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1213920"
}
},
{
"@type": "ScholarlyArticle",
"name": "What complements complement in transplant-associated thrombotic microangiopathy?",
"datePublished": "2022-08-09",
"url": "https://questionsmedicales.fr/article/35942659",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bjh.18402"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009422"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies du système nerveux central",
"item": "https://questionsmedicales.fr/mesh/D002493"
},
{
"@type": "ListItem",
"position": 4,
"name": "Encéphalopathies",
"item": "https://questionsmedicales.fr/mesh/D001927"
},
{
"@type": "ListItem",
"position": 5,
"name": "Épilepsie",
"item": "https://questionsmedicales.fr/mesh/D004827"
},
{
"@type": "ListItem",
"position": 6,
"name": "Syndromes épileptiques",
"item": "https://questionsmedicales.fr/mesh/D000073376"
},
{
"@type": "ListItem",
"position": 7,
"name": "Épilepsies myocloniques",
"item": "https://questionsmedicales.fr/mesh/D004831"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Épilepsies myocloniques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Épilepsies myocloniques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Épilepsies myocloniques",
"description": "Comment diagnostiquer une épilepsie myoclonique ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une épilepsie myoclonique ?\nL'épilepsie myoclonique est-elle héréditaire ?\nQuel rôle joue l'EEG dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Épilepsies myocloniques",
"description": "Quels sont les symptômes principaux ?\nLes myoclonies sont-elles douloureuses ?\nPeut-on avoir des crises sans myoclonies ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLes crises peuvent-elles survenir la nuit ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Épilepsies myocloniques",
"description": "Peut-on prévenir les crises myocloniques ?\nQuels déclencheurs sont à éviter ?\nL'éducation est-elle importante pour la prévention ?\nLe suivi médical est-il essentiel ?\nLes activités physiques sont-elles sûres ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Épilepsies myocloniques",
"description": "Quels médicaments sont utilisés pour traiter ?\nY a-t-il des traitements non médicamenteux ?\nComment évaluer l'efficacité du traitement ?\nLes traitements sont-ils à vie ?\nQuels effets secondaires des médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Épilepsies myocloniques",
"description": "Quelles complications peuvent survenir ?\nL'épilepsie myoclonique peut-elle affecter la vie quotidienne ?\nY a-t-il un risque accru de dépression ?\nLes crises peuvent-elles entraîner des accidents ?\nComment gérer les complications psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Épilepsies myocloniques",
"description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque d'épilepsie myoclonique ?\nLes troubles neurologiques augmentent-ils le risque ?\nLe stress est-il un facteur de risque ?\nLes infections cérébrales sont-elles un risque ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=Complement+Activation&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une épilepsie myoclonique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical, l'examen neurologique et l'EEG."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'EEG, l'IRM cérébrale et des tests sanguins peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une épilepsie myoclonique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des secousses musculaires rapides, souvent sans perte de conscience, sont typiques."
}
},
{
"@type": "Question",
"name": "L'épilepsie myoclonique est-elle héréditaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines formes peuvent être héréditaires, nécessitant une évaluation familiale."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'EEG dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'EEG aide à détecter les anomalies électriques typiques des épilepsies myocloniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des myoclonies, des crises généralisées et parfois des absences."
}
},
{
"@type": "Question",
"name": "Les myoclonies sont-elles douloureuses ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les myoclonies ne sont généralement pas douloureuses, mais peuvent être gênantes."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des crises sans myoclonies ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent avoir des crises généralisées sans myoclonies."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la fréquence des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles survenir la nuit ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des crises myocloniques peuvent survenir pendant le sommeil."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les crises myocloniques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un traitement adéquat et l'évitement des déclencheurs."
}
},
{
"@type": "Question",
"name": "Quels déclencheurs sont à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress, la fatigue, et la consommation d'alcool peuvent déclencher des crises."
}
},
{
"@type": "Question",
"name": "L'éducation est-elle importante pour la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur la maladie aide les patients à mieux gérer leur condition."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il essentiel ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'ajuster le traitement et de surveiller les symptômes."
}
},
{
"@type": "Question",
"name": "Les activités physiques sont-elles sûres ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines activités peuvent être sûres, mais il faut éviter les sports à risque."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticonvulsivants comme le valproate et le lamotrigine sont couramment prescrits."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme la thérapie comportementale et la diététique peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des crises et les effets secondaires."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils à vie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, le traitement est à long terme, mais certains peuvent réduire ou arrêter."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des médicaments ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure fatigue, vertiges et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des blessures dues aux crises et des troubles psychologiques."
}
},
{
"@type": "Question",
"name": "L'épilepsie myoclonique peut-elle affecter la vie quotidienne ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut impacter la vie sociale, professionnelle et la qualité de vie."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de dépression ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes épileptiques ont un risque plus élevé de dépression et d'anxiété."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles entraîner des accidents ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les crises peuvent provoquer des accidents, notamment lors de la conduite."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications psychologiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un soutien psychologique et des thérapies adaptées peuvent aider à gérer ces complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, les traumatismes crâniens et certaines infections sont des facteurs."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'épilepsie myoclonique ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'épilepsie myoclonique peut débuter à tout âge, mais souvent dans l'enfance ou l'adolescence."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, d'autres troubles neurologiques peuvent augmenter le risque d'épilepsie myoclonique."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut déclencher des crises chez les personnes prédisposées."
}
},
{
"@type": "Question",
"name": "Les infections cérébrales sont-elles un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme la méningite, peuvent augmenter le risque d'épilepsie."
}
}
]
}
]
}
Chronic antibody-mediated rejection in kidney transplantation is a common cause of graft loss in the late post-transplant period. In this process, the role of the classical complement activation pathw...
Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate i...
Forty-three patients (23 women; median age, 69 years) were enrolled in this prospective study and underwent phacoemulsification and vitrectomy. We measured Schirmer's test (ST) and CAPs in the tears a...
The median ST (8.5 mm) at baseline increased to 16 mm at 4 days ( P < 0.001) and 10 mm at 1 month (P = 0.44). The C3a levels (1202 pg/ml) at baseline increased to 2753 pg/ml at 4 days (P < 0.001), and...
The CAPs levels in tears increased after vitrectomy combined with cataract surgery. A preoperative deficit in tear secretion might induce prolonged complement activation and delayed recovery of ocular...
Complement component 5 (C5) targeting therapies are clinically beneficial in patients with acetylcholine receptor antibody...
In a case-control study, concentrations of C3a, C5a and sC5b9 were simultaneously quantified, indicating general activation of the complement system, whether via the classical and lectin pathways (C4a...
Treatment-naïve patients with AChR-Ab...
Markers indicative of complement activation are prominently increased in patients with AChR-Ab MG despite standard immunosuppressive therapies. Complement inhibition proximal to C5 cleavage should be ...
The complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a macrocyclic peptide that binds and ...
The interaction of zilucoplan with C5, including for clinical C5 R885 variants, was investigated using surface plasmon resonance (SPR), hemolysis assays, and ELISA. The interference of C5b6 formation ...
Zilucoplan specifically bound human complement C5 with high affinity, competitively inhibited the binding of C5 to C3b, and blocked C5 cleavage by C5 convertases and the assembly of the cytolytic memb...
Our findings demonstrate that zilucoplan uses a dual mode of action to potently inhibit the activation of C5 and terminal complement pathway including wild-type and clinical R885 variants that do not ...
Transplant-associated thrombotic microangiopathy remains a lethal complication of haematopoietic stem cell transplant and not all patients respond to terminal complement inhibitors. Qi et al. show tha...
The intravascular formation of neutrophil extracellular traps (NETs) is a trigger for coagulation and blood vessel occlusion. NETs are released from neutrophils as a response to strong inflammatory si...
In the present study, we used different microfluidic setups in combination with fluorescence microscopy to investigate the influence of neutrophil-derived extracellular DNA fibers on blood rheology, i...
We found that extended DNA fiber networks decelerate blood flow and promote intravascular occlusion of blood vessels independent of the plasmatic coagulation. Associated with the DNA dependent occlusi...
In conclusion, we found that DNA fibers as the principal component of NETs are sufficient to induce blood aggregation even in the absence of the coagulation system. Moreover, we discovered that comple...
Hidradenitis suppurativa (HS) is a chronic auto-inflammatory skin disease with a complex and multifactorial pathogenesis involving both the innate and adaptive immune system. Despite limited evidence ...
Sepsis is characterized by a dysregulated immune response to infection. The complement system plays an important role in the host defence to pathogens. However, exaggerated complement activation might...
Secondary analysis of complement factors in a prospective study in 209 hospitalized sepsis patients, of whom the majority presented with shock. Concentrations of complement factors C3, C3a, C3c, C5, C...
The concentration of complement factors in plasma of severely ill sepsis patients indicated profound activation of the complement system (all P < 0.01 compared to healthy controls). Spearman rank corr...
Once an infection progresses to severe sepsis or septic shock, the complement pathway is already profoundly activated and is no longer related to a dysregulated inflammatory response, nor to clinical ...
Complement activation through antibody-antigen complexes is crucial in various pathophysiological processes and utilized in immunotherapies to eliminate infectious agents, regulatory immune cells, or ...
To prepare nanoscale ultrasound contrast agents (Nano-UCAs) and examine the role of their surface charge in complement activation and phagocytosis....
We analyzed serum proteins present in the corona formed on Nano-UCAs and evaluated two important protein markers of complement activation (C3 and SC5b-9). The effect of surface charge on phagocytosis ...
When Nano-UCAs were incubated with human serum, they were opsonized by various blood proteins, especially C3. Highly charged Nano-UCAs, whether positive or negative, were favorably opsonized by comple...
Charged Nano-UCAs show a higher tendency to activated complement system, and are efficiently engulfed by macrophages. The present results provide meaningful insights into the role of the surface charg...